维持性血液透析患者循环微小RNA-155、程序性细胞死亡因子4 表达与钙磷代谢紊乱的关系

doi:10.3969/j.issn.1671-4091.2021.08.009

摘要/Abstract

摘要： 【摘要】目的探讨维持性血液透析(maintenance hemodialysis，MHD)患者血清微小RNA-155(microRNA-155，miR-155)、程序性细胞死亡因子4(programmed cell death 4，PDCD4)表达与钙磷代谢紊乱的关系。方法选取2018 年9 月～2020 年10 月于三河市燕郊人民医院行MHD≥3 个月且病情控制稳定的慢性肾脏病患者86 例为研究组，同期选择体检的健康人群80 例为对照组。利用酶联免疫吸附法检测血清PDCD4、高敏C 反应蛋白(hs-CRP)水平，全自动生化分析仪检测血清白蛋白、血红蛋白、血钙、血磷、全段甲状旁腺激素(iPTH)水平，荧光定量PCR 技术检测血清miR-155 水平，分析研究组与对照组的一般资料信息，比较研究组和对照组血清miR-155、PDCD4 水平差异。根据MHD 患者年龄、透析龄、透析频率进行分组，比较各组血清miR-155、PDCD4 水平。以血清miR-155、PDCD4 水平均值为分界点分为高表达组和低表达组，分析各组MHD 患者钙磷代谢情况。利用多因素Logistic 回归分析影响MHD 患者发生钙磷代谢紊乱的危险因素。结果研究组血清白蛋白水平低于对照组(t=8.848，P＜0.001)，血磷、iPTH、hs-CRP、
miR-155、PDCD4水平均高于对照组(t 值分别为10.491、3.578、10.988、16.298、19.419，P 值分别为＜0.001、＜0.001、＜0.001、＜0.001、＜0.001)；年龄≥60 岁、透析龄≥3 年、透析频率＞2 次/w 的MHD 患者血清miR-155、PDCD4 水平均分别高于年龄＜60 岁、透析龄＜3 年、透析频率2 次/w 的MHD 患者(t 值分别为13.723、7.773、4.846、15.740、10.206、5.154，P 值分别为＜0.001、＜0.001、＜0.001、＜0.001、＜0.001、＜0.001)；miR-155 和PDCD4 高表达组患者血钙、血磷、iPTH 达标患者比例均分别低于miR-155 和PDCD4 低表达组患者，miR-155、PDCD4 表达情况与血钙、血磷、iPTH 水平有关(Z 值分别为=21.333、7.898、7.407、15.712、9.234、7.899，P 值分别为＜0.001、0.019、0.025、＜0.001、0.010、0.019)；多因素Logistic 回归分析结果显示，血清白蛋白(OR=2.431,95% CI:1.388～4.258，P=0.002)、miR- 155(OR=2.715,95% CI:1.433～5.144,P=0.002)、PDCD4 (OR=2.629,95%CI:1.429～4.836，P=0.002)是影响MHD 患者钙磷代谢紊乱的独立危险因素。结论MHD 患者血清miR-155、PDCD4 水平与血钙、血磷、iPTH 代谢有关，高水平的miR-155、PDCD4 是影响MHD 患者钙磷代谢紊乱的独立危险因素。

关键词: 维持性血液透析, 微小RNA-155, 程序性细胞死亡因子4, 钙磷代谢紊乱, 关系

Abstract: 【Abstract】Objective To investigate the relationship between serum levels of microRNA- 155 (miR-155) and programmed cell death 4(PDCD4) and disorder of calcium and phosphorus metabolism in maintenance hemodialysis (MHD) patients. Methods A total of 86 MHD patients treated during September 2018 to October 2020 in Yanjiao People's Hospital of Sanhe City for more than 3 months and with stable conditions were recruited as the study group, and 80 healthy people for physical check-up in our hospital were selected as the control group. Serum PDCD4 and high-sensitivity C-reactive protein (hs-CRP) were assayed by ELISA,
hemoglobin and serum albumin, calcium, phosphorus and intact parathyroid hormone (iPTH) were detected by automatic biochemical analyzer, and serum miR-155 was determined by fluorescence quantitative PCR. General information of the patients was analyzed. Serum miR-155 and PDCD4 levels were compared between the study group and the control group. The MHD patients were further divided into subgroups based on age, dialysis vintage and dialysis frequency, and serum miR-155 and PDCD4 levels were then compared among the subgroups. The MHD could be further grouped into the high expression group and the low expression group based on their average serum miR-155 and PDCD4 levels; calcium and phosphorus metabolism were then analyzed between the two groups. Logistic regression analysis was used to evaluate the risk factors for calcium and phosphorus metabolism disorder in MHD patients. Results Serum albumin was significantly lower in the study group than in the control group (t=8.848, P<0.001), but serum phosphorus, iPTH, hs-CRP, miR-155, and PDCD4 levels were significantly higher in the study group than in the control group (t=10.491, 3.578, 10.988, 16.298 and 19.419 respectively; P<0.001). Serum miR-155 and PDCD4 levels were higher in the MHD patients with age ≥60 years, dialysis vintage ≥3 years and dialysis frequency >2 times/week than those with age <60 years, dialysis vintage <3 years and dialysis frequency 2 times/week (t=13.723, 7.773, 4.846, 15.740, 10.206 and 5.154, respectively; P<0.001). The compliance rates of serum calcium, phosphorus and iPTH were lower in the high expression group than in the low expression group. The expression levels of miR- 155 and PDCD4 were correlated with the serum levels of calcium, phosphorus and iPTH (Z=21.333, 7.898, 7.407, 15.712, 9.234 and 7.899, respectively; P <0.001, 0.019, 0.025, <0.001, 0.010 and 0.019, respectively). Multivariate logistic regression analysis showed that serum albumin (OR=2.431, 95% CI: 1.38～
4.258, P=0.002), miR-155 (OR=2.715, 95% CI: 1.433～5.144, P=0.002) and PDCD4 (OR=2.629, 95% CI:1.429～4.836, P=0.002) were the independent risk factors for calcium and phosphorus metabolism disorder in MHD patients (P<0.05). Conclusion Serum miR-155 and PDCD4 levels were correlated with calcium and phosphorus metabolism and iPTH in MHD patients. High serum levels of miR-155 and PDCD4 were the independent risk factors for calcium and phosphorus metabolism disorder in MHD patients.

Key words: Maintenance hemodialysis, microRNA-155, Programmed cell death 4, Calcium and phosphorus metabolism disorder, Relationship

中图分类号:

R589.5

徐建男, 王淑明, 张建新, 王月华, 康京月, 刘畅. 维持性血液透析患者循环微小RNA-155、程序性细胞死亡因子4 表达与钙磷代谢紊乱的关系[J]. 中国血液净化, 2021, 20(08): 540-545.

参考文献

[1]Ohnishi T, Kimachi M, Fukuma S, et al. Postdialysis Hypokalemia and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis[J]. Clin J Am Soc Nephrol, 2019, 14(6):873-881.
[2]Gazda AJ, Aponte MMP, De GA, et al. A crossroads at the understanding of pulmonary hypertension in end stage renal disease[J]. Heart Lung, 2021, 50(1):232-233.
[3]Tudoran M, Ciocarlie T, Mates A, et al. Pulmonary hypertension in patients with end stage renal disease undergoing hemodialysis[J]. Niger J Clin Pract, 2020, 23(2):198-204.
[4]Metzinger-Le Meuth V, Metzinger L. miR-223 and other miRNA's evaluation in chronic kidney disease: Innovative biomarkers and therapeutic tools[J]. Noncoding RNA Res, 2019, 4(1):30-35.
[5]Xia H, Zhao Y. miR-155 is high-expressed in polycystic ovarian syndrome and promotes cell proliferation and migration through targeting PDCD4 in KGN cells[J]. Artif Cells Nanomed Biotechnol, 2020, 48(1):197-205.
[6]陈续红, 刘帝, 刘烨歆, 等. 维持性血液透析患者钙磷代谢紊乱的影响因素及其与肾性贫血的相关性[J]. 临床肾脏病杂志, 2016, 16(12):728-733.
[7]Zhu M, Dou L, Zhu M, et al. Variability of serum phosphorus and its association with mortality among hemodialysis patients[J]. Clin Nephrol, 2018, 90(2):79-86.
[8]Janjua TK, Mukhtar KN, Naveed AK, et al. Frequency of maintenance hemodialysis patients meeting K/DOQI criteria for serum calcium, phosphorus, calcium phosphorus product and PTH levels; a single institutional experience from Pakistan: a cross sectional study[J]. Pan Afr Med J, 2019, 33(1):183-189.
[9]Schjenken JE, Moldenhauer LM, Zhang B, et al. MicroRNA miR-155 is required for expansion of regulatory T cells to mediate robust pregnancy tolerance in mice[J]. Mucosal Immunol, 2020, 13(4):609-625.
[10]Chen X, Zhang XB, Li DJ, et al. miR-155 facilitates calcium oxalate crystal-induced HK-2 cell injury via targeting PI3K associated autophagy[J]. Exp Mol Pathol, 2020, 115(1):1-9.
[11]Khoshmirsafa M, Kianmehr N, Falak R, et al. Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis[J]. Int J Rheum Dis, 2019, 22(3):458-467.
[12]Navarroza RV, Zamora LD, Navarra SV. Serotonin syndrome masquerading as disease flare in lupus nephritis with end‐stage renal disease[J]. Int J Rheum Dis, 2019, 22(10):1933-1936.
[13]Fan B, Jin Y, Zhang H, et al. MicroRNA-21 contributes to renal cell carcinoma cell invasiveness and angiogenesis via the PDCD4/c-Jun (AP-1) signalling pathway[J]. Int J Oncol, 2020, 56(1):178-192.
[14]Madera S, Chervo MF, Chiauzzi VA, et al. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis[J]. Horm Cancer, 2020, 11(5-6):218-239.
[15]熊佳易, 陈蕾, 魏燕,等. PDCD4对卵巢癌细胞生长、凋亡及p-p38MAPK、p-STAT3水平影响[J]. 中国医学前沿杂志(电子版), 2019, 11(2):144-148.
[16]Lu K, Chen Q, Li M, et al. Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer[J]. Free Radic Biol Med, 2020, 159(1):150-163.
[17]Ding L, Gao F, Zhang M, et al. Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome[J]. Fertil Steril, 2016, 105(5):1330-1337.
[18]Yang R, Liu S, Wen J, et al. Inhibition of maternally expressed gene 3 attenuated lipopolysaccharide-induced apoptosis through sponging miR-21 in renal tubular epithelial cells[J]. J Cell Biochem, 2018, 119(9):7800-7806.
[19]吴丹, 刘胜阳, 任丽丽. 碳酸镧对维持性血液透析患者钙磷水平的影响及安全性分析[J]. 河北医学, 2020, 26(9):1532-1536.